| 1 |
33898931 | Bone Marrow Mesenchymal Stromal Cell-mediated Resistance in Multiple Myeloma Against NK Cells can be Overcome by Introduction of CD38-CAR or TRAIL-variant. | 2021 May |
1 |
| 2 |
34377229 | Kras mutation subtypes distinctly affect colorectal cancer cell sensitivity to FL118, a novel inhibitor of survivin, Mcl-1, XIAP, cIAP2 and MdmX. | 2021 |
2 |
| 3 |
30285798 | An ABCG2 non-substrate anticancer agent FL118 targets drug-resistant cancer stem-like cells and overcomes treatment resistance of human pancreatic cancer. | 2018 Oct 3 |
1 |
| 4 |
28337384 | Topoisomerase I (Top1): a major target of FL118 for its antitumor efficacy or mainly involved in its side effects of hematopoietic toxicity? | 2017 |
1 |
| 5 |
26692923 | FL118, a novel camptothecin analogue, overcomes irinotecan and topotecan resistance in human tumor xenograft models. | 2015 |
1 |
| 6 |
24329001 | Antitumor activity of FL118, a survivin, Mcl-1, XIAP, and cIAP2 selective inhibitor, is highly dependent on its primary structure and steric configuration. | 2014 Feb 3 |
4 |
| 7 |
24959385 | Anticancer drug FL118 is more than a survivin inhibitor: where is the Achilles' heel of cancer? | 2014 |
1 |
| 8 |
23573360 | An intravenous (i.v.) route-compatible formulation of FL118, a survivin, Mcl-1, XIAP, and cIAP2 selective inhibitor, improves FL118 antitumor efficacy and therapeutic index (TI). | 2013 |
2 |
| 9 |
23029106 | A novel small molecule FL118 that selectively inhibits survivin, Mcl-1, XIAP and cIAP2 in a p53-independent manner, shows superior antitumor activity. | 2012 |
2 |